Collectively, these data suggest that although high expression of both ACACA and FASN consistently correlates to reduced survival in tumors independently of their MYCN status, FASN seems to be a better prognosis marker candidate for neuroblastoma patients. The gene discussed is MYCN; the disease is neuroblastoma.